Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: Response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (Infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–1683
Journal article published in 2016 by
S. Gentileschi 
,
C. Barreca,
F. Bellisai,
G. Biasi,
M. G. Brizi,
R. De Stefano,
M. Fabbroni,
A. Fioravanti,
E. Frati,
E. Selvi,
A. Vitale,
L. Cantarini,
B. Frediani,
M. Galeazzi
,
C. Barreca,
F. Bellisai,
G. Biasi,
M. G. Brizi,
R. De Stefano,
M. Fabbroni,
A. Fioravanti,
E. Frati,
E. Selvi,
A. Vitale,
L. Cantarini,
B. Frediani,
M. Galeazzi
